China FDA Publishes Draft Measures to Accelerate Medical Device Approvals


The China Food and Drug Administration (previously known as the State Food and Drug Administration) (the “CFDA”) has published drafts of two tentative measures, Fast Track Approval Process of Innovative Medical Devices and Circular on Simplification of Dossier Required for Medical Device License Renewal and Amendment, for public comments through March 31, 2013. Both measures reflect the CFDA’s intention to expedite the approval process for certain medical device products.

- Pursuant to the draft of the Fast Track Approval Process of Innovative Medical Devices, the CFDA will establish a new office with dedicated reviewers in charge of review and approval of innovative medical devices. The applicant for the fast track approval must be a medical device manufacturing company licensed in China and the subject product must satisfy the following criteria: (i) the core technology related to the product must be registered in China as an invention patent that the manufacturer owns or is licensed to use; (ii) the product’s working or functioning mechanism is first seen in China, its performance or safety improves significantly compared with similar products, and its technology is worldwide pioneering and has evident value in the clinical application; and (iii) the manufacturer has completed the early stage R&D and the product’s basic design, the R&D activities are authentic and under control, and the R&D data is complete and traceable. The provincial Food and Drug Administrations (the “Provincial FDAs”) will decide whether the application is eligible for the fast track approval process. Once the application is admitted to the fast track, the CFDA and the Provincial FDAs will give priority to such application in the entire approval process, including regulatory testing and technical review. In addition, the CFDA and the Provincial FDAs are required to appoint a liaison official to respond to and guide the applicant in a timely manner.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.